Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arformoterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 18/20 | 0.80 |
| ▸ | ADRB1 | P08588 | 6/20 | 0.80 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.80 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.80 |
| ▸ | TSHR | P16473 | 3/20 | 0.80 |
| ▸ | DRD2 | P14416 | 2/20 | 0.80 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.80 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.80 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.80 |
| ▸ | PGR | P06401 | 1/20 | 0.80 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
| ▸ | DRD3 | P35462 | 1/20 | 0.80 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arformoterol SCHEMBL4536455 | 0.92 | ADRB2 (0.87) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Arformoterol SCHEMBL4917618 | 0.91 | ADRB2 (0.86) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Arformoterol SCHEMBL6426856 | 0.90 | ADRB2 (0.77) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Arformoterol SCHEMBL750656 | 0.90 | ADRB2 (0.77) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Arformoterol SCHEMBL1697132 | 0.90 | ADRB2 (0.65) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Arformoterol SCHEMBL4247 | 0.89 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Arformoterol SCHEMBL3679114 | 0.89 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Formoterol SCHEMBL6528975 | 0.89 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Arformoterol SCHEMBL117865 | 0.89 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4MAPK1 | |
| Arformoterol SCHEMBL6547706 | 0.89 | ADRB2 (1.00) | ADRB2ADRB1ADRB3CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277669-A1 | USES OF UROLITHINS | AMAZENTIS SA (CH) | 2023-09-07 | — | — | US | disclosed |
| WO-2023161453-A1 | USES OF UROLITHINS | AMAZENTIS SA (CH) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023154746-A2 | COMPOSITIONS AND METHODS FOR CHARACTERIZING LOW FREQUENCY MUTATIONS | THE BROAD INSTITUTE, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-3938368-B1 | COMPOUND FORM HAVING ENHANCED BIOAVAILABILITY AND FORMULATIONS THEREOF | PTC THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20230087562-A1 | COMPOSITIONS AND METHODS OF TREATING CARDIAC HYPERTROPHY AND HEART FAILURE | UNIV CASE WESTERN RESERVE (US) | 2023-03-23 | — | — | US | disclosed |
| EP-4138782-A1 | PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICAL PRODUCTS OF HETERODIMERIC HUMAN INTERLEUKIN-15 (HETIL-15) | Novartis AG (CH) | 2023-03-01 | — | — | EP | disclosed |
| US-20230016609-A1 | MESOPOROUS SILICA NANOPARTICLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-01-19 | — | — | US | disclosed |
| EP-4100425-A1 | CHO CELL EXPRESSING IL-15 HETERODIMERS | Novartis AG (CH) | 2022-12-14 | — | — | EP | disclosed |
| CN-115443127-A | Pharmaceutical compositions and products of heterodimers human interleukin-15 (HETIL-15) | 诺华股份有限公司 | 2022-12-06 | — | — | CN | disclosed |
| CN-115023436-A | CHO cells expressing IL-15 heterodimers | 诺华股份有限公司 | 2022-09-06 | — | — | CN | disclosed |
| US-20050042664-A1 | Humanization of antibodies | MEDIMMUNE, INC. (US) | 2005-02-24 | — | — | US | disclosed |
| WO-2005012877-A2 | SYSTEMS AND METHODS FOR ANTIBODY ENGINEERING | DNA TWOPOINTO INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005003302-A2 | NOVEL METHODS TO MODULATE MAST CELLS | MEDIMMUNE, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| US-20050002934-A1 | Recombinant IL-9 antibodies and uses thereof | MEDIMMUNE, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004108122-A1 | GLYCYRRHIZIN OR DERIVATIVES THEREOF FOR TREATING OR PREVENTING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) | JOHANN WOLFGANG GOETHE UNIVERSITY (DE) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004091510-A2 | RECOMBINANT IL-9 ANTIBODIES AND USES THEREOF | MEDIMMUNE, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004091519-A2 | METHODS OF PREVENTING OR TREATING RESPIRATORY CONDITIONS | MEDIMMUNE, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-20040018200-A1 | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations | MEDIMMUNE, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003105894-A1 | STABILIZED LIQUID ANTI-RSV ANTIBODY FORMULATIONS | MEDIMMUNE, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003106644-A2 | STABILIZED ANTI-RESPIRATORY SYNCYTIAL VIRUS (RSV) ANTIBODY FORMULATIONS | MEDIMMUNE, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230087562-A1 | COMPOSITIONS AND METHODS OF TREATING CARDIAC HYPERTROPHY AND HEART FAILURE | NR1H2, FABP3, NR1H3 | ADRB2 46/4885ADRB1 18/4885ADRB3 33/4885 |
| US-20230277669-A1 | USES OF UROLITHINS | CD47, CD69, CD44 | ADRB2 3986/4885ADRB1 2956/4885ADRB3 3469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.